Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK Interaction of DHP2306R1 and DHP2306R2 in Healthy Volunteers
NCT06395155Phase 1Completed
- Sponsor
- Daehwa Pharmaceutical Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of celecoxib oral solution and eperisone in Musculoskeletal pain (6 arms), sponsored by Daehwa Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Concentration-time Curve over the Dosing Interval at Steady State at Day 5 and Maximum Plasma Concentration at Steady State at Day 5. Started Oct 2023; status: completed.
02
Drugs
celecoxib oral solutioneperisone
03
Conditions
Musculoskeletal pain
Beyond the preview
Go deeper on NCT06395155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06395155.